FEROX STRATEGIES

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 20, 2026

Lobbying activity 3

Trade (domestic/foreign)

General issues related to tariffs.

Taxation/Internal Revenue Code

General issues related to rare disease treatment development.

Health Issues

General issues related to rare disease treatment.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.